InsideArbitrage Event Driven Monitor – March 7, 2023

Quick updates on the event driven strategies we follow on InsideArbitrage.

Subscribe to receive our Event Driven Monitor by email every morning before the market opens.

Merger Arbitrage

1. The merger of TCR2 Therapeutics (TCRR) with Adaptimmune Therapeutics (ADAP) for -$156.04 million in an all stock deal. Under the terms of the agreement, TCR2 stockholders will receive 1.5117 Adaptimmune ADS for each TCR2 share.
2. Neovasc (NVCN) announced that its shareholders approved the previously-announced acquisition of the company by Shockwave Medical.
3. F-star Therapeutics (FSTX) and invoX Pharma Limited extended the End Date of the Merger Agreement in order to provide additional time for the Parties to finalize an agreement with CFIUS and to complete the ongoing tender offer whose expiration date has been extended to March 8, 2023.

Only plus or premium subscribers can access this post. Subscribe today.